Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4673128 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2TP53CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2415202 | 0.88 | — | — | |
| SCHEMBL9266877 | 0.80 | HTT (0.31) | SMN1; SMN2 | |
| SCHEMBL3028991 | 0.79 | HTT (0.31) | — | |
| SCHEMBL2751239 | 0.79 | HRH3 (0.38) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL234449 | 0.79 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3950967 | 0.78 | PPM1B (0.41) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL2921227 | 0.76 | CHRNB2 (0.37) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3953036 | 0.75 | ADRB2 (0.36) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL2833747 | 0.75 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740587-A4 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS LLC (US) | 2009-07-15 | — | — | EP | claimed |
| US-7217702-B2 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2007-05-15 | — | — | US | claimed |
| EP-1740587-A2 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | Adenosine Therapeutics, LLC (US) | 2007-01-10 | — | — | EP | claimed |
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2005-12-22 | — | — | US | claimed |
| WO-2005097140-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2005-10-20 | — | — | WO | claimed |
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| EP-1740587-A4 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1539754-A4 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080176858-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-07-24 | — | — | US | disclosed |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHIRON CORPORATION | 2005-11-17 | — | — | US | disclosed |
| WO-2005097140-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6376506-B1 | REACTING SULFAMOYL OXAZOLIDONE WITH (1,2,3,4)-TETRAHYDRO-BETA-CARBOLINE TO FORM INHIBITOR; USED TO TREAT ARTHRITIS, OSTEOPOROSIS, PERIODONTAL DISEASE, CARDIOVASCULAR DISEASES, MULTIPLE SCLEROSIS, AND TUMORS | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADORA2A, ADORA2B, ADORA3 | SMN1; SMN2 942/4885TP53 4285/4885CHRNB2 39/4885 |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHEK1, CHEK2, RAD1 | SMN1; SMN2 1651/4885TP53 18/4885CHRNB2 3617/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | SMN1; SMN2 2956/4885TP53 2043/4885CHRNB2 3928/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | SMN1; SMN2 976/4885TP53 2/4885CHRNB2 3068/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | SMN1; SMN2 2790/4885TP53 2069/4885CHRNB2 4021/4885 |
| US-20080176858-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADORA2A, ADORA1, ADORA2B | SMN1; SMN2 1651/4885TP53 4141/4885CHRNB2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.